JAZZ U.S.: Nasdaq


    After Hours
    Last Updated: Sep 8, 2022 4:50 p.m. EDT Delayed quote

    $ 151.55

    0.00 0.00%
    After Hours Volume: 23.91K
    Close Chg Chg %
    $151.55 -0.45 -0.30%
    Advanced Charting
    Volume: 491.18K 65 Day Avg: 487.13K
    101% vs Avg
    149.38 Day Range 151.88
    117.64 52 Week Range 169.98

    Your Watchlists

    Customize 江湖电竞最新版比赛(江湖电竞投注app网站)

    Have Watchlists? Log in to see them here or sign up to get started.

    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    JAZZ Overview

    Key Data

    • Open $151.28
    • Day Range 149.38 - 151.88
    • 52 Week Range 117.64 - 169.98
    • Market Cap $9.53B
    • Shares Outstanding 62.68M
    • Public Float 60.76M
    • Beta 0.78
    • Rev. per Employee $1.088M
    • P/E Ratio N/A
    • EPS -$0.86
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 2.78M 08/15/22
    • % of Float Shorted 4.57%
    • Average Volume 487.13K


    5 Day
    • -3.56%
    1 Month
    • -1.75%
    3 Month
    • 2.36%
    • 18.96%
    1 Year
    • 12.75%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 18 Full Ratings

    Recent News

    Jazz Pharmaceuticals Phase 3 Nabiximols Study in MS Misses Main Endpoint >JAZZ

    Read full story

    FDA stalled on CBD for now: Analyst

    Redx to Get $5 Mln on Tumor Drug Milestone With US Regulator

    Jazz Pharmaceuticals started at buy with $194 stock price target at UBS

    Jazz, Werewolf sign licensing deal worth up to $1.2 billion

    Shares of Werewolf Therapeutics Inc. jumped 10.8% in premarket trading on Thursday after the company announced a licensing deal with Jazz Pharmaceuticals Plc worth up to $1.2 billion. Jazz now has exclusive development a...

    Read full story

    Biotech Stocks Could Make a Comeback. The ‘M&A Stars’ Are in Line.

    Read full story

    Pfizer’s Arena Pharma deal may lead drug company to a cannabis-based treatment

    Read full story

    Vertical Wellness becomes first house of CBD brands to hit public markets

    Jazz's leukemia drug gets approved by the FDA

    Shares of Jazz Pharmaceuticals plc gained 3.5% in premarket trading on Thursday, the day after the Food and Drug Administration said it had approved the company's acute lymphocytic leukemia treatment Rylaze. The therapy i...

    Jazz updates 2021 guidance after closing acquisition of GW Pharmaceuticals

    Jazz Pharmaceuticals Plc updated its guidance for 2021 to reflect its acquisition of GW Pharmaceuticals Inc., which closed in early May. Jazz now expects revenue of $3.02 billion to $3.18 billion in 2021, compared with it...

    CORRECTED: Jazz Pharmaceuticals now sees 2021 adj. EPS of $13.40 to $14.70 vs prior $15.65 to $16.85

    CORRECTED: Jazz Pharmaceuticals now sees 2021 loss per share $4.70 to $2.00 vs. prior guidance for EPS of $8.30 to $1.045

    Jazz Pharmaceuticals now sees 2021 revenue of $3.020 bln to $3.180 bln vs. prior $2.550 bln to $2.700 bln

    Jazz Pharmaceuticals updates 2021 guidance to include GW Pharma

    Read full story

    Cannabinoid company backed by rapper Snoop Dogg headed for London IPO

    Read full story

    Inflation Is Coming. 5 Stocks to Buy Now.

    Read full story

    Canopy Growth to acquire Supreme Cannabis in latest tie-up in busy weed sector

    Read full story

    Watch the warnings coming from the stock market’s sell signals

    Read full story

    Cannabis stocks rally anew as $7 billion GW Pharma deal spurs interest in weed and its medical benefits

    UPDATE: Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock, GW soars 46% premarket

    Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per share in cash and $20 in...

    Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why

    Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.

    on Zacks.com

    Which “Strong Buy” Cannabis Stock Could Offer the Highest Upside Potential?

    Cannabis stocks continue to be clobbered this year due to the lack of favorable reforms and the persistent delay in the legalization of cannabis at the federal level. Marijuana continues to be a Schedule 1 substance in the...

    on TipRanks.com

    2 Growth Stocks That Are Beating Amazon Without Breaking a Sweat

    on Motley Fool

    Jazz (JAZZ) Up 4% Since Last Earnings Report: Can It Continue?

    Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    on Zacks.com

    Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate

    Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.

    on Zacks.com

    How Much Upside is Left in Jazz (JAZZ)? Wall Street Analysts Think 29%

    The average of price targets set by Wall Street analysts indicates a potential upside of 29.1% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings esti...

    on Zacks.com

    Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

    on Zacks.com

    2 Top Healthcare Stocks Defying the Bear Market

    on Motley Fool

    Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication

    Jazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy drug, Epidiolex, in children and adolescents suffering from epilepsy with Myoclonic-Atonic Seizures (EMAS).

    on Zacks.com

    Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

    on Benzinga.com

    RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug

    RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease

    on Zacks.com

    Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures

    on Benzinga.com

    Wall Street Analysts Predict a 25% Upside in Jazz (JAZZ): Here's What You Should Know

    The mean of analysts' price targets for Jazz (JAZZ) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings esti...

    on Zacks.com

    5 Biotech Stocks in the Buy Zone This Week

    on StockNews.com

    Top 5 2nd Quarter Trades of DeepCurrents Investment Group LLC

    Top 5 2nd Quarter Trades of DeepCurrents Investment Group LLC

    on GuruFocus.com

    Wellesley Asset Management Buys 2, Sells 3 in 2nd Quarter

    Wellesley Asset Management Buys 2, Sells 3 in 2nd Quarter

    on GuruFocus.com

    M.D. SASS INVESTORS SERVICES, INC. Buys 3, Sells 2 in 2nd Quarter

    M.D. SASS INVESTORS SERVICES, INC. Buys 3, Sells 2 in 2nd Quarter

    on GuruFocus.com

    Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up

    Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.

    on Zacks.com

    Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss

    Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.

    on Zacks.com

    Why Axsome Therapeutics Topped the Market Today

    on Motley Fool

    Jazz Pharmaceuticals PLC

    Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.


    Name Chg % Market Cap
    Johnson & Johnson 0.80% $431.37B
    Pfizer Inc. 2.06% $258.9B
    Merck & Co. Inc. 0.63% $220.07B
    Novartis AG -0.33% CHF173.37B
    Bristol Myers Squibb Co. 0.90% $146.82B
    Sanofi S.A. -0.06% €101.51B
    GSK PLC -0.01% £54.36B
    Teva Pharmaceutical Industries Ltd. 2.46% ₪32.51B
    Avadel Pharmaceuticals PLC ADR 2.03% $352.39M
    Oncopeptides AB 11.42% kr2.75B